Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Walvax Biotech Gains Majority Control of Fengmao Biotech

publication date: Jul 10, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Yunnan Walvax Biotechnology, a vaccine company, obtained a 51% stake in Shanghai Fengmao Biotechnology Co. Walvax will establish subsidiaries of Fengmao to produce five monoclonal antibodies and a sustained-release version of the anemia treatment EPO. Walvax will invest 102 million RMB ($16 million) in cash, while other investors will contribute a monoclonal technology valued at 93 million RMB ($14.6 million). More details....

Stock Symbol: (SHE: 300142)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners